Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy(FLUORO) | active not recruiting | Phase 2 | 15 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06764017 | CHiR Therapy for Elderly DLBCL Intolerant to Chemo | recruiting | Phase 2 | 30 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06758037 | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy(HiR+X) | recruiting | Phase 2 | 50 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04867915 | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | recruiting | — | 12,500 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | terminated | — | 36 | CelgeneINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | enrolling by invitation | Phase 1 / Phase 2 | 22 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01437709 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant | completed | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT04872413 | Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial | completed | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788652 | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06794268 | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158386 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06779435 | A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL | recruiting | — | 400 | Ruijin HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06826118 | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823960 | Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)(ZanOs) | recruiting | — | 59 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT03992339 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma(SEARCH) | completed | Phase 2 | 60 | Antengene CorporationINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | terminated | Phase 1 / Phase 2 | 13 | Deepa JagadeeshOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06813573 | Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma(EVOLITION) | recruiting | N/A | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | terminated | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | terminated | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 7 | Feb 4, 2025 | clinicaltrials |
| NCT04599634 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06806488 | Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas(MarZoLyOss) | recruiting | — | 160 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT03476655 | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | completed | — | 40 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Mar 30, 2025source: clinicaltrials